Royal Bank of Canada Boosts Stake in DENTSPLY SIRONA Inc. $XRAY

Royal Bank of Canada boosted its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 137.7% in the 1st quarter, Holdings Channel reports. The firm owned 256,701 shares of the medical instruments supplier’s stock after purchasing an additional 148,702 shares during the period. Royal Bank of Canada’s holdings in DENTSPLY SIRONA were worth $2,978,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in XRAY. Southpoint Capital Advisors LP acquired a new stake in shares of DENTSPLY SIRONA in the first quarter valued at $116,000,000. AQR Capital Management LLC lifted its stake in DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after acquiring an additional 6,970,086 shares in the last quarter. Armistice Capital LLC lifted its stake in DENTSPLY SIRONA by 1,044.0% during the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after acquiring an additional 5,234,587 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in DENTSPLY SIRONA by 662.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after acquiring an additional 4,003,606 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after acquiring an additional 2,172,343 shares during the period. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on XRAY. Mizuho cut their price target on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Barclays lowered their price objective on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating for the company in a research note on Thursday, June 4th. Barrington Research set a $15.00 price objective on shares of DENTSPLY SIRONA in a report on Monday, August 10th. BMO Capital Markets reaffirmed a “market perform” rating and set a $13.00 target price on shares of DENTSPLY SIRONA in a research note on Friday, August 7th. Finally, Piper Sandler upped their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $13.38.

DENTSPLY SIRONA Stock Performance

Shares of XRAY opened at $11.59 on Friday. DENTSPLY SIRONA Inc. has a 1 year low of $9.40 and a 1 year high of $14.86. The stock has a market capitalization of $2.31 billion, a PE ratio of -4.21, a PEG ratio of 1.38 and a beta of 0.85. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.07 and a current ratio of 1.63. The stock has a 50-day simple moving average of $11.94 and a 200-day simple moving average of $11.86.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. The firm had revenue of $898.00 million for the quarter, compared to analyst estimates of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, analysts predict that DENTSPLY SIRONA Inc. will post 1.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Brian P. Mckeon acquired 10,000 shares of the company’s stock in a transaction on Friday, June 12th. The shares were bought at an average cost of $10.12 per share, with a total value of $101,200.00. Following the transaction, the director owned 10,000 shares in the company, valued at approximately $101,200. This trade represents a ? increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael J. Barber acquired 15,175 shares of DENTSPLY SIRONA stock in a transaction dated Thursday, June 11th. The stock was purchased at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the acquisition, the director directly owned 55,943 shares in the company, valued at approximately $552,716.84. This represents a 37.22% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 35,160 shares of company stock worth $351,179 in the last 90 days. Corporate insiders own 0.46% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.